Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant omicron-delta COVID-19 vaccine
- Development stage
- Unknown
- Lead developer
- Zhifei Longcom Biologic Pharmacy
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intranasal
01
Overview
Recombinant omicron-delta COVID-19 vaccine is an investigational **recombinant protein-subunit COVID-19 vaccine** developed by Anhui Zhifei Longcom Biologic Pharmacy for prevention of COVID-19. The product contains 25 micrograms of DO-RBD protein per 0.5 mL dose. DO-RBD is a tandem recombinant antigen comprising receptor-binding-domain sequences from SARS-CoV-2 Delta and Omicron variants, produced in Chinese hamster ovary cells. Vaccination is intended to induce humoral and cellular immune responses against the SARS-CoV-2 spike receptor-binding domain and thereby prevent respiratory disease caused by SARS-CoV-2 infection. The vaccine has been evaluated in registered adult clinical studies, including a Phase 3 study in Uzbekistan. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05574985))
- Other names
- Omicron-Delta recombinant novel coronavirus protein vaccineDO-RBD vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on recombinant omicron-delta COVID-19 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant omicron-delta COVID-19 vaccine.